Staff

Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

2019 Protiviti and Shared Assessments Survey Finds Board Involvement a Key Indicator of Vendor Risk Management Maturity; Most Organizations Will Drop Vendors to De-Risk

SANTA FE, N.M. and MENLO PARK, Calif., April 9, 2019 /PRNewswire/ -- Global consulting firm Protiviti and the Shared Assessments Program,...

error: Content is protected !!